 ImmunityBio Inc NASDAQ: IBRX has announced that Papillary disease Cohort B of its Phase 23 study of intravesical BCG plus Anktiva met its primary endpoints with disease-free survival of 57 at 12 months. Non-muscle invasive bladder cancer NMIBC makes up 75-85 of all bladder cancers in the U.S.; approximately 90 of NMIBC cases are papillary. 